A global health company offering medical insurance through Cigna Healthcare and pharmacy and care services through Evernorth, home to brands like Express Scripts, Accredo, and MDLive. It was born from the 1982 merger of Connecticut General Life Insurance and Insurance Company of North America — and the name "Cigna" simply stitches the C and INA initials together. Its oldest ancestor, INA, dates to 1792 as America's first marine insurer.
Cigna Q2 net income rose 8% to $1.66B as Cigna Healthcare margin gains offset Evernorth income decline
margins improved while Evernorth's slipped. rose 6.7% to $71.7B and rose 10.2% to $6.29, driven by Cigna Healthcare's 17% adjusted income increase from better U.S. Employer margins. The quarter shows recovering, but stayed negative at $421M.
Key takeaways
pre-tax rose 17% in Q2 on improved U.S. Employer margins, while its adjusted revenues increased 9% from higher premium rates in employer insured and stop loss.
adjusted revenues grew 6% to $61.5B in Q2, driven by claims composition in , but its pre-tax fell 2% due to client-focused initiatives.
Shareholders' increased 8% to $1,660M for Q2 and 16% to $3,314M for H1, primarily reflecting higher from .
Section summaries
Management's Discussion and Analysis
Cigna Q2 2026 net income rose 8% to $1.66B, driven by Cigna Healthcare margin gains and Evernorth claims composition growth.
⌄
Shareholders' increased 8% to $1.66B for Q2 and 16% to $3.31B for H1, primarily reflecting higher adjusted income from .
rose 6.7% to $71.7B and rose 10.2% to $6.29; rose 0.3 points to 3.7% and rose 16.0% to $2,676M .
was -$421M in Q2, improving from -$1,886M in Q1 but remaining negative; H1 operating cash flow improved to $710M from $34M on timing and factoring settlements.
The company repurchased 0.9M shares for $250M in H1 2026, down from $2.6B a year ago, and held $6.6B in cash and short-term investments as of June 30.
What changed
: flagged from 79.8% in Q1, the Q2 MD&A cites improved U.S. Employer margins and 17% rise, reversing the 2025 trend of ratio increases to 84.4%.
: flagged for recovery after Q1 fell 41% to $1.1B; H1 improved to $710M from $34M, though Q2 alone was -$421M versus -$1,886M in Q1.
Remaining $0.6B sale proceeds: no deployment noted this quarter; only $250M of repurchases occurred in H1 versus $2.6B a year earlier.
Evernorth versus growth: Q2 revenue rose 6% but adjusted income fell 2%, continuing the gap flagged through 2025 as client-focused initiatives offset growth.
still down from transaction: adjusted revenues rose 9% Q2 but premiums fell 10% for H1 due to the completed sale.
What to watch
trajectory in Q3 2026 after the Q2 margin improvement to 79.8%-level U.S. Employer gains
recovery in H2 2026 after Q2 alone was -$421M
Resumption of and deployment of remaining proceeds after H1 buybacks totaled only $250M
Evernorth trend versus its 6% Q2 growth as client-focused initiatives continue
adjusted revenues grew 6% to $61.5B in Q2, driven by claims composition in , but pre-tax adjusted income fell 2% due to client-focused initiatives.
pre-tax adjusted income rose 17% in Q2 on improved U.S. Employer margins, while adjusted revenues increased 9% from higher premium rates in employer insured and stop loss.
Total pharmacy revenues increased 7% in Q2, while premiums rose 8% for the quarter but fell 10% for H1 due to the impact.
improved to $710M in H1 2026 from $34M, driven by timing and factoring settlements, partially offset by lower insurance liabilities.
The company repurchased 0.9M shares for $250M in H1 2026, down from $2.6B a year ago, and had $6.6B in cash and short-term investments as of June 30.
Quantitative and Qualitative Disclosures About Market Risk
Information responsive to this item is contained under the caption "Market Risk" in Item 2 above, Management's Discussion and Analysis of Financial Condition and Results of Operations, and is incorporated herein by reference.
⌄
Information responsive to this item is contained under the caption "Market Risk" in Item 2 above, Management's Discussion and Analysis of Financial Condition and Results of Operations, and is incorporated herein by reference.
The information contained under "Legal and Regulatory Matters" in Note 14 to the Consolidated Financial Statements is incorporated herein by reference.
⌄
The information contained under "Legal and Regulatory Matters" in Note 14 to the Consolidated Financial Statements is incorporated herein by reference.
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025.
⌄
For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A - "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025.